Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

 Finally, just last week, we announced a positive interim analysis over of our proof-of-concept Phase 2 clinical trial legend evaluating the combination of lani with SGLT-2 inhibitor empagliflozin. The study was designed to potentially demonstrate an additive effect of the combination and the management of weight gain that can be observed in some patient treated with Lanifibranor. The study met its primary endpoint, which was the reduction of HbA1c, demonstrated that the combination addresses the moderate ...

Ed Arce - H.C. Wainwright Lucy Codrington - Jefferies & Co. Evan Wang - Guggenheim Securities Jacob Mekhael - KBC Securities So let me turn to the highlights. It's been a very busy first half, and I would say, very exciting for Inventiva. And I'll start by going over some of the key highlights regarding our key program lanifibranor, including an update on the global Phase 3 NATiV3, our Phase 2 combo study with lani and empagliflozin. And of course come back on the investigator initiated study in patients wi ...

Table of Contents Exhibit 99.1 INVENTIVA S.A. A joint-stock company (société anonyme) with a share capital of 517,528.07 euros Registered office: 50, rue de Dijon, 21121 Daix, France Dijon Trade and Companies Register 537 530 255 INTERIM FINANCIAL REPORT FOR THE SIX MONTHS ENDED JUNE 30, 2023 Table of Contents Table of contents | 1. | | Interim Financial Report | 3 | | --- | --- | --- | --- | | | 1.1. | General overview of activities | 3 | | | 1.2. | Significant events in the first half of 2023 | 5 | | | 1. ...

Inventiva S.A. (NASDAQ:IVA) 2022 Full Year Results Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Frédéric Cren – Chief Executive Officer Jean Volatier – Chief Financial Officer Michael Cooreman – Chief Medical Officer Conference Call Participants Seamus Fernandez – Guggenheim Securities Annabel Samimy – Stifel Ed Arce – H.C. Wainwright Frédéric Gomez – Pharmium Securities Operator Good day and thank you for standing by. Welcome to the Inventiva 2022 Full Year Results Call and Webca ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ...

Developing innovative therapies in NASH NasdagListed This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. These statements include, but are not limited to, forecasts, targets and estimates with respect to Inventiva's pre-clinical programs and clinical trials, including recruitment, ...

Inventiva S.A. (NASDAQ:IVA) Q2 2022 Earnings Conference Call September 22, 2022 8:00 AM ET Company Participants Frédéric Cren - Co-Founder and CEO Pierre Broqua - Co-Founder and CSO Michael Cooreman - Chief Medical Officer Jean Volatier - Chief Financial Officer Philip Duong - Head, Investment Conference Call Participants Ed Arce - H.C. Wainwright Jeroen Van den Bossche - KBC Securities Alex Cogut - Bryan, Garnier Delphine Le Louët - Société Générale Operator Good day and thank you for standing by. Welcome ...

inventiva | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------|-------|------------------------|-------|-------|------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | Developing innovative therapies in | | | | | NASH | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Corporate Presentation | | | | | | | | June 2022 | | | | | | | | | | | | | | | | | | | EURONEXT DISCLAIMER This presentation contains fo ...

Inventiva S.A. (NASDAQ:IVA) Q4 2021 Earnings Conference Call March 8, 2022 8:00 AM ET Company Participants Frédéric Cren - Chairman, Chief Executive Officer & Co-Founder Pierre Broqua - Chief Scientific Officer & Co-Founder Michael Cooreman - Chief Medical Officer Jean Volatier - Chief Financial Officer Conference Call Participants Lucy Codrington - Jefferies Jeroen Van den Bossche - KBC Securities Jean-Jacques Le Fur - Bryan, Garnier Ivan Wang - Guggenheim Securities Delphine Le Louët - Société Générale Op ...